Valneva Shares Drop 2% and Approach Key Support at €2.26
Midday sees the Lyon-based biotech extending its downturn, as the SBF 120 also trends negatively. The stock is sinking into a technically fragile zone, below all its moving averages, and continues to be weighed down by a deteriorated annual trajectory.
Valneva Stock Dips Close to Critical Support Level
Valneva shares decline by 1.96% to €2.30 at mid-session, within an SBF 120 that is down by 0.43%. The stock is now less than 2% above its support level at €2.26, which was previously tested at the end of May and during last week's sessions.
The stock is trading below its 20-day moving average (MM20) at €2.52, showing a deviation of -8.81%, below its 50-day moving average (MM50) at €2.54, and significantly under its 200-day moving average (MM200) at €3.74, over 38% below the latter. The RSI at 40 indicates a persistent selling trend, though it has not yet reached the oversold zone.
Over the week, the stock has lost 12% and has seen a nearly 50% decline over three months, indicating a consistently deteriorating trend.
Stock Trajectory Continues to Be Hampered by Reorganization and Lowered Guidance
Today's movement follows a pattern that began in mid-May. On May 13, during the announcement of the first quarter 2026 results, the company reported a 37% decrease in revenue and a net loss of €32.1 million, along with a reorganization plan aimed at reducing operational expenses by 25 to 35% and global workforce by 10 to 15%.
On this occasion, the company also adjusted its 2026 revenue forecast to between €135 and €150 million. Factors cited during this announcement included decreased sales of third-party products and unfavorable trends in travel vaccine adoption.
The €2.26 support level remains the most closely watched technical threshold in the short term. A break below this level would open an area without recent reference points; maintaining it could preserve the possibility of stabilization after a nearly 50% drop since the start of the quarter.
